Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002818 · ClinicalTrials.gov registry record · Phase 1
High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00002818 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 15 participants.
The verdict
NCT00002818, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Deoxycytidine may protect patients from the side effects of high-dose cytarabine. PURPOSE: Phase I trial to study the effectiveness of high-dose cytarabine given with deoxycytidine in treating patients who have refractory acute myelogenous leukemia or other lymphoma or leukemia.
Interventions
- DRUG deoxycytidine
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 1995-02 |
| Est. Completion | 2001-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002818
The ClinicalTrials.gov registry entry for NCT00002818 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which deoxycytidine is the first listed.
NCT00002818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002818 about?
NCT00002818 is a clinical study titled "High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Deoxycytidine may protect patients from the side effects of high-dose cytarabine. PURPOSE: Phase I trial to study the effectiveness of high-dose cytarabine given with deoxycytidi...
What is the current status of trial NCT00002818?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 1995-02. Estimated completion is 2001-02.
What interventions are being tested in trial NCT00002818?
The interventions under investigation include: deoxycytidine (DRUG), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00002818?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.